216 related articles for article (PubMed ID: 26844556)
1. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids.
Hara A; Endo S; Matsunaga T; Soda M; El-Kabbani O; Yashiro K
Arch Biochem Biophys; 2016 Nov; 609():69-76. PubMed ID: 27665999
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Wang C; Yan R; Luo D; Watabe K; Liao DF; Cao D
J Biol Chem; 2009 Sep; 284(39):26742-8. PubMed ID: 19643728
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.
Kabir A; Endo S; Toyooka N; Fukuoka M; Kuwata K; Kamatari YO
J Biochem; 2017 Feb; 161(2):215-222. PubMed ID: 28003428
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Verma M; Martin HJ; Haq W; O'Connor TR; Maser E; Balendiran GK
Eur J Pharmacol; 2008 Apr; 584(2-3):213-21. PubMed ID: 18325492
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
[TBL] [Abstract][Full Text] [Related]
8. Cancer biomarker AKR1B10 and carbonyl metabolism.
Balendiran GK; Martin HJ; El-Hawari Y; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):134-7. PubMed ID: 19028477
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Endo S; Matsunaga T; Soda M; Tajima K; Zhao HT; El-Kabbani O; Hara A
Biol Pharm Bull; 2010; 33(5):886-90. PubMed ID: 20460771
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
12. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of polyphenols isolated from Rhus verniciflua on Aldo-keto reductase family 1 B10.
Song DG; Lee JY; Lee EH; Jung SH; Nho CW; Cha KH; Koo SY; Pan CH
BMB Rep; 2010 Apr; 43(4):268-72. PubMed ID: 20423612
[TBL] [Abstract][Full Text] [Related]
15. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the inhibition of AKR1B10 by caffeic acid phenethyl ester (CAPE).
Zhang L; Zhang H; Zheng X; Zhao Y; Chen S; Chen Y; Zhang R; Li Q; Hu X
ChemMedChem; 2014 Apr; 9(4):706-9. PubMed ID: 24436249
[TBL] [Abstract][Full Text] [Related]
17. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Endo S; Matsunaga T; Kuwata K; Zhao HT; El-Kabbani O; Kitade Y; Hara A
Bioorg Med Chem; 2010 Apr; 18(7):2485-90. PubMed ID: 20304656
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447
[TBL] [Abstract][Full Text] [Related]
19. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
20. Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.
Díez-Dacal B; Gayarre J; Gharbi S; Timms JF; Coderch C; Gago F; Pérez-Sala D
Cancer Res; 2011 Jun; 71(12):4161-71. PubMed ID: 21507934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
